Overall verdict
Buy
7.8/10
1-year performance
+27.13%
Score breakdown
Up 27.1% over 1 year, 84% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Valuation 2.9/10.
28 analysts, target +0.1% vs the price.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system ; Dexcom G6, a CGM system ; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions ;
Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin ; Dexcom Share, a remote monitoring system ; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nasdaq
United States
CEO
Jacob Leach
Founded
1999
Employees
11 100
Revenue / employee
420 000 USD
Next earnings
October 29, 2026 (estimated)
Institutional holders
- BlackRock, Inc.10.01%
- VANGUARD CAPITAL MANAGEMENT LLC6.60%
- VANGUARD PORTFOLIO MANAGEMENT LLC5.14%
- STATE STREET CORP4.81%
- Invesco Ltd.4.00%
- BAILLIE GIFFORD & CO3.87%
- GEODE CAPITAL MANAGEMENT, LLC3.25%
- ALLIANCEBERNSTEIN L.P.3.06%
- UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC2.95%
- Other institutions57.12%
966 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
92.59 USD
52-week low
54.11 USD
1-year performance
27.13%
Rising
Year-to-date performance
31.67%
Rising
Drawdown
-6.45%
Mild pullback
Position in the 52-week range
84% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 3.9 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| DexCom | 577 417 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 3.9 times as much as the world ETF.
- Worst fall:-67 % between November 2021 and November 2025. 10,000 € placed at the top fell to 3 303 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
DexCom earned 8 times as much as the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- DexCom: 577 417 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 79.00 USD - 107.40 USD (2 methods agree)
The price implies growth of 7.14% per year; the company grows at 10.55%.
Gross margin 63.6%, net margin 20.1%, ROIC 25.2%, ROE 38.5%.
Net margin
20.12%
Exceptional
Sector 8.18%|S&P 12.97%
Gross margin
63.57%
Fair
Return on equity (ROE)
38.49%
Exceptional
Sector 6.97%|S&P 16.52%
Return on invested capital (ROIC)
25.24%
Exceptional
Free cash flow margin (FCF)
28.27%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.41x
High
Margin stability
12.8 pts
Very uneven
Revenue to net income
Growth
8.6/10Revenue up 13.1% over 1 year, 19.3% a year over 5, EPS 10.5% a year over 5.
Revenue (trailing 12 months)
5.0Md USD
Revenue growth (1y)
13.08%
Hyper-growth
Revenue growth (3y)
60.22%
Strong
EPS growth (1y)
43.63%
Hyper-growth
EPS CAGR (5y)
10.55%
Fair
EPS revisions (3 months)
2.88%
Revised up
Valuation
2.9/10P/E 34.2x, forward P/E 34.7x, EV/EBITDA 22.8x, PEG 3.24. The multiple sits in the 16th percentile of its own 5-year history.
P/E (TTM)
34.2x
Fair
Sector 28.9x|S&P 23.3x
Forward P/E
34.7x
Expensive
EV / EBITDA
22.8x
Expensive
Sector 15.8x|S&P 14.6x
PEG
3.24
Very expensive
Sector 1.79|S&P 0.86
Fair value (reverse DCF)
89.24 USD
Fairly priced
P/E vs its own 5-year history
among the 16% lowest valuations
Far cheaper than usual
Market cap
33.1Md USD
Financial strength
10.0/10Cash covers 139.2% of the debt, net debt/EBITDA -0.5x.
Net debt / EBITDA
-0.5x
Net cash
Gearing (net debt / equity)
-20.93%
Net cash
Cash
1.9Md USD
Cash / market cap
5.88%
Tight
Cash / total debt
139.23%
Net cash
Interest coverage
102.6x
Very solid
Net debt
-549M USD
Equity
2.6Md USD
Closed daily candles, 2 years
Last close on September 25, 2026: 86.63 USD
- MM2087.58
- MM5085.13
- MM20072.57
- RSI 1448.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+4.01%
200-day average slope, 3 months
+7.89%
50-day average slope, 1 month
+8.43%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.49 % per day
Volatility change
-39.71%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 2.49 (10) | 2.66 (25) | 5 230 (27) | 1 666 (19) | 974 (11) |
| 2027 | 2.97 (10) | 3.12 (25) | 5 800 (27) | 1 921 (19) | 1 149 (11) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 18, 2026.
Same sub-industry: 191 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DXCM | 7.8 | 7.1 | 33.1Md USD | 34.2x | 20.1 % | 13.1 % | 25.2 % | -0.5x | 4.2 % | 27.1 % | ||
| 2 | BSX | 7.0 | 7.2 | 64.7Md USD | 18.1x | 17.5 % | 7.5 % | 10.5 % | 1.8x | 5.6 % | -55.2 % | ||
| 3 | MDT | 7.0 | 7.1 | 114Md USD | 22.0x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 5.4 % | -7.0 % | ||
| 4 | SYK | 6.9 | 7.5 | 105Md USD | 28.3x | 14.4 % | 9.4 % | 10.0 % | 1.7x | 4.5 % | -26.0 % | ||
| 5 | ABT | 6.6 | 6.3 | 179Md USD | 33.5x | 11.6 % | 13.0 % | 7.5 % | 0.5x | 4.4 % | -24.7 % | ||
| 6 | ISRG | 6.5 | 6.8 | 141Md USD | 45.6x | 28.4 % | 18.5 % | 17.4 % | -1.6x | 2.3 % | -8.0 % | ||
| 7 | SHL | 6.3 | 6.5 | 47.2Md USD | 19.1x | 9.6 % | 1.8 % | 7.4 % | 2.7x | 5.4 % | -15.6 % | ||
| 8 | EW | 6.0 | 5.6 | 50.0Md USD | 51.5x | 15.0 % | 13.6 % | 8.7 % | -2.0x | 2.9 % | 15.8 % | ||
| 9 | BDX | 5.4 | 5.1 | 49.7Md USD | 55.1x | 6.2 % | 5.4 % | 3.2 % | 3.4x | 5.1 % | 26.3 % |
